Article

FDA and States Discuss Regulation of Drug Compounders

SILVER SPRING, Md. — The Food and Drug Administration conferred with public health officials from 50 states on Wednesday about how best to strengthen rules governing compounding pharmacies in the wake of a national meningitis outbreak caused by a tainted pain medication produced by a Massachusetts pharmacy.

It was the first public discussion of what should be done about the practice of compounding, or tailor-making medicine for individual patients, since the F.D.A. commissioner, Dr. Margaret Hamburg, testified in Congress last month about the need for greater federal oversight of large compounding pharmacies. So far, 620 people in 19 states have been sickened in the outbreak, and 39 of them have died.

Read the full story: http://nyti.ms/Ufqz2t

Source: The New York Times

Related Videos
Kimberly Westrich, MA, chief strategy officer, NPC
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Raj Chovatiya, MD, PhD, MSCI.
1 expert in this video
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo